Recruiting

Observational Study

Sponsor:

Milton S. Hershey Medical Center

Code:

NCT05998629

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels

Standard of Care laboratory procedure for measurement of sweat

Study Details

Brief summary:

Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of limitations. The objectives of this study are: 1)To evaluate a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels as a potential low-cost but potentially accurate test to diagnoses cystic fibrosis (CF) and 2) To evaluate measurements of sweat chloride (Cl) using this same system in comparison to the standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for assessment of the diagnosis of CF. This is a single institution study performed solely at PSH-HMC. Study participants will include 1) adults 18 years of age or older capable of providing signed and dated informed consent, 2) subjects with an established known diagnosis of cystic fibrosis (CF) or healthy volunteers, and 3) able to understand and speak English language. Exclusion criteria include: 1) any medical condition or disorder known to potentially interfere with accurate measurements of sweat chloride and 2) inability to understand and speak the English language. Cystic Fibrosis (CF) subjects will be identified from the population of eligible patients receiving medical care at Penn State Health- Milton S. Hershey Medical Center (PSH-HMC). Healthy donor volunteers will be recruited from various members of the PSH-HMC CF clinical care team, members of the Division of Allergy, Pulmonary and Critical Care (both faculty and trainees) at PSH-HMC, and PSU-University Park research team. The total projected number of combined enrolled subjects is 30. This is a single day single time study that will require approximately 60 minutes of subject participation. Potential risks include a) side effects from pilocarpine iontophoresis sweat test collection (pain, skin discomfort, blisters, rarely burns and b) loss of confidentiality. There will be no cost to subjects for study participation. There will be no reimbursement financially for study participation. There is no benefit to subjects for study participation. There is the potential benefit to medical science via identification of improved method to accurately measure sweat chloride for diagnosis of CF.

Conditions

Cystic Fibrosis

Study ID

NCT05998629

Start date

Jul 1, 2024

Status verified date

Jan, 2026

Completion date

Dec 1, 2026

Anticipated

Primary completion date

Dec 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • adults 18 years of age or older capable of providing signed and dated informed consent,
  • subjects with an established known diagnosis of cystic fibrosis (CF) or healthy volunteers,
  • able to understand and speak English language.

Exclusion Criteria:

  • any medical condition or disorder known to potentially interfere with accurate measurements of sweat chloride
  • inability to understand and speak the English language.

Study Design

Enrollment

30 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Healthy control subjects experimental device

a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels for healthy control subjects

active comparator: Healthy control subjects standard of care

standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for measurement of sweat chloride concentrations for healthy control subjects

experimental: Cystic Fibrosis Subjects experimental device

a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels for cystic fibrosis subjects

active comparator: Cystic Fibrosis Subjects standard of care

standard clinical laboratory procedures routinely performed in the Clinical Laboratory at Penn State Health Milton S. Hershey Medical Center (PSH-HMC), Hershey, PA for measurement of sweat chloride concentrations for cystic fibrosis subjects

Interventions

a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels

a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels

Standard of Care laboratory procedure for measurement of sweat

a skin-interface sweat measurement using a smart-watch type device

Primary outcome measure

  • Sweat chloride concentration using standard of care lab assessment [ Time Frame: Single point in time measurement 60 minutes after device attachment ]

Central Contacts and Locations

Central contacts

Locations

Penn State Milton S. Hershey Medical Center

Recruiting

Hershey, Pennsylvania, United States, 17033

Contacts

More Information

Sponsor

Milton S. Hershey Medical Center

Last update posted

Jan 9, 2026

Last verified

Jan, 2026

Keywords

  • Sweat Chloride Test
  • Cystic Fibrosis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Milton S. Hershey Medical Center on 2026-01-09.